Self-Assembling Peptide "BATMAN" Nanoparticle Fights Deadly Post-Sepsis Infections

A self-assembling peptide nanoparticle targets bacteria while simultaneously rejuvenating exhausted immune cells to fight sepsis-related secondary infections.

Qing, Guangchao et al.·Science translational medicine·2025·low-moderateAnimal StudyAnimal Study
RPEP-13148Animal Studylow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
low-moderate
Sample
N=Not specified (animal study)
Participants
Mice with sepsis-associated immunosuppression

What This Study Found

BATMAN peptide nanoparticle simultaneously targets bacteria and rejuvenates immunosuppressed macrophages via tuftsin-FcγR signaling in preclinical sepsis.

Key Numbers

Components: ubiquicidin (bacteria-targeting), cholesteryl hemisuccinate (lipase-sensitive), FFVLK (assembly), tuftsin (immune activation); tested in mouse sepsis model.

How They Did This

Self-assembling peptide nanoparticle design with preclinical evaluation in sepsis-associated secondary infection models.

Why This Research Matters

Sepsis kills millions annually and secondary infections are the leading cause of late sepsis deaths — this dual-action approach addresses both problems.

The Bigger Picture

This represents a new paradigm in sepsis treatment — fighting infection while simultaneously repairing the damaged immune system.

What This Study Doesn't Tell Us

Preclinical study — human sepsis is highly heterogeneous and may respond differently. Manufacturing complexity of multi-domain peptide nanoparticles.

Questions This Raises

  • ?Can BATMAN be manufactured at scale for clinical trials?
  • ?Would it work in different types of secondary infection beyond the models tested?

Trust & Context

Key Stat:
Sci Transl Med Dual-action peptide nanoparticle published in a top translational medicine journal
Evidence Grade:
High-impact preclinical study in a leading translational journal — compelling proof of concept but requires clinical validation.
Study Age:
Published in 2025, introducing a novel multi-functional peptide approach to sepsis.
Original Title:
FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection.
Published In:
Science translational medicine, 17(830), eadv0313 (2025)
Database ID:
RPEP-13148

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What is BATMAN in this context?

An acronym for Bacteria-Targeted Transformable Macrophage Nanorejuvenator — a self-assembling peptide nanoparticle that fights both bacteria and immune exhaustion.

Why are secondary infections after sepsis so dangerous?

Sepsis exhausts the immune system, leaving patients unable to fight new infections — BATMAN aims to restore immune function while targeting bacteria directly.

Read More on RethinkPeptides

Cite This Study

RPEP-13148·https://rethinkpeptides.com/research/RPEP-13148

APA

Qing, Guangchao; Zhang, Yuxuan; Wang, Yongchao; Li, Xianlei; Luo, Ting; Zhang, Fuxue; Ni, Qiankun; Hu, Runjing; Shan, Shaobo; Zhang, Hong; Yuan, Rui; Gan, Yaling; Liang, Xing-Jie; Luo, Yang. (2025). FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection.. Science translational medicine, 17(830), eadv0313. https://doi.org/10.1126/scitranslmed.adv0313

MLA

Qing, Guangchao, et al. "FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection.." Science translational medicine, 2025. https://doi.org/10.1126/scitranslmed.adv0313

RethinkPeptides

RethinkPeptides Research Database. "FcγR-targeted tuftsin clusters rejuvenate macrophages in pre..." RPEP-13148. Retrieved from https://rethinkpeptides.com/research/qing-2025-fcrtargeted-tuftsin-clusters-rejuvenate

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.